Table 1.
Patient Characteristics (n=347).
| ET (n=143) | PV (n=129) | Pre-PMF (n=44) | PMF (n=31) | |||||
|---|---|---|---|---|---|---|---|---|
| Age (yr), median (range) | 62 (15-88) | 64 (18-91) | 63.5 (22-88) | 68.5 (40-88) | ||||
| Male, n (%) | 73 (51.0) | 82 (63.6) | 25 (56.8) | 21 (67.7) | ||||
| Palpable splenomegaly, n (%) | 0 (0.0) | 11 (8.5) | 4 (9.1) | 16 (51.6) | ||||
| Laboratory findings | ||||||||
| WBC, ×109/L | 11.0±4.5 | 14.7±6.2 | 14.5±10.2* | 13.7±11.0 | ||||
| Monocyte, ×109/L | 0.6±0.4 | 0.7±0.4 | 0.8±0.4* | 1.0±0.8 | ||||
| Hemoglobin, g/dL | 13.6±2.2 | 18.3±2.5 | 13.0±2.8 | 10.3±2.5 | ||||
| Platelet, ×109/L | 946.5±244.9 | 510.9±288.4 | 1,093.9±461.1* | 424.8±327.5 | ||||
| LDH, ×UNL | 1.1±0.4 | 1.3±0.5 | 1.6±0.7* | 2.0±1.5 | ||||
| Driver gene mutation, n (%) | ||||||||
| JAK2V617F | 80/121 (68.6) | 102/112 (91.1) | 24/37 (64.9) | 15/23 (65.3) | ||||
| CALR | 14/121 (11.6) | - | 5/34 (14.7) | 5/23 (21.7) | ||||
| MPL | 0/12 (0.0) | - | 0/3 (0.0) | 0/3 (0.0) | ||||
| JAK2 exon12 | - | 6/112 (5.4) | - | - | ||||
| Abdomen CT taken at diagnosis, n (%) | 80 (55.9) | 69 (53.5) | 20 (45.5) | 19 (61.3) | ||||
| IPSET, n (%) | ||||||||
| Low | 45 (31.5) | - | - | - | ||||
| Intermediate | 42 (29.4) | - | - | - | ||||
| High | 56 (39.2) | - | - | - | ||||
| IPSS, n (%) | ||||||||
| Low | - | - | 23 (52.3) | 5 (16.1) | ||||
| Intermediate-1 | - | - | 17 (38.6) | 8 (25.8) | ||||
| Intemediate-2 | - | - | 3 (6.8) | 12 (38.7) | ||||
| High | - | - | 1 (2.3) | 6 (19.4) | ||||
| Comorbidity, n (%) | ||||||||
| Hypertension | 51 (35.7) | 77 (59.7) | 22 (50.0) | 11 (35.5) | ||||
| Diabetes mellitus | 19 (13.3) | 32 (24.8) | 9 (20.5) | 7 (22.6) | ||||
| Chronic kidney disease | 21 (14.7) | 30 (23.3) | 9 (20.5) | 4 (12.9) | ||||
| Smoking | 28 (19.6) | 53 (41.1) | 14 (31.8) | 4 (12.9) | ||||
| Treatments, n (%) | ||||||||
| Cytoreductive treatment | 101 (75.4) | 106 (82.2) | 34 (77.3) | 17 (54.8) | ||||
| Aspirin | 128 (89.5) | 121 (93.8) | 38 (86.4) | 12 (38.7) | ||||
| Thrombosis, n (%)** | 37 (25.9) | 39 (30.2) | 13 (29.5) | 1 (3.2) | ||||
| FU (yr), median (range) | 3.6 (0.2-24.1) | 6.2 (0.2-26.5) | 4.8 (0.2-22.7) | 3.2 (0.1-19.7) |
ET: essential thrombocythemia, PV: polycythemia vera, pre-PMF: prefibrotic/early myelofibrosis, LDH: lactate dehydrogenase, UNL: upper normal limit, CT: computed tomography, IPSET: International Prognostic Score for Essential Thrombocythemia, IPSS: International Prognostic Scoring System, FU: follow-up
*p<0.05 compared to ET.
**Thrombosis before and at the time of diagnosis.